Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 5/20 | 0.56 |
| ▸ | CCKAR | P32238 | 4/20 | 0.56 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | MMP9 | P14780 | 2/20 | 0.55 |
| ▸ | MMP8 | P22894 | 2/20 | 0.55 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 3/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27462135 | 0.93 | ERAP2 (0.60) | CCKBRCCKARERAP2MMP2MMP9 | |
| SCHEMBL27462136 | 0.93 | ERAP2 (0.60) | CCKBRCCKARERAP2MMP2MMP9 | |
| SCHEMBL28478871 | 0.88 | ACE (0.64) | MMP2MMP9MMP8ACEPPARG | |
| SCHEMBL21001587 | 0.86 | MEN1 (0.64) | ACEPPARG | |
| SCHEMBL25189279 | 0.86 | MEN1 (0.64) | ACEPPARG | |
| SCHEMBL25264480 | 0.86 | MEN1 (0.64) | ACEPPARG | |
| SCHEMBL25183154 | 0.86 | MEN1 (0.64) | ACEPPARG | |
| SCHEMBL22206848 | 0.86 | MEN1 (0.64) | ACEPPARG | |
| SCHEMBL21001123 | 0.86 | MEN1 (0.64) | ACEPPARG | |
| SCHEMBL25264926 | 0.86 | MEN1 (0.64) | ACEPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0615522-B1 | MURAMYL COMPOUNDS FOR TREATMENT OF SEPTIC SHOCK | PEPTECH UK LTD (GB) | 1999-09-22 | — | — | EP | claimed |
| EP-0768888-A1 | USE OF MURAMYL PEPTIDE COMPOUNDS | PEPTECH (UK) LIMITED (GB) | 1997-04-23 | — | — | EP | claimed |
| WO-1996001645-A1 | USE OF MURAMYL PEPTIDE COMPOUNDS | PEPTECH(UK) LIMITED (GB) | 1996-01-25 | — | — | WO | claimed |
| EP-0615522-A1 | MURAMYL COMPOUNDS FOR TREATMENT OF SEPTIC SHOCK | PEPTECH (UK) LIMITED (GB) | 1994-09-21 | — | — | EP | claimed |
| WO-1993010148-A1 | MURAMYL COMPOUNDS FOR TREATMENT OF SEPTIC SHOCK | PEPTECH (UK) LIMITED (GB) | 1993-05-27 | — | — | WO | claimed |
| WO-2005007676-A2 | GLYCOPEPTIDES FOR THE TREATMENT OF ALS AND OTHER METABOLIC AND AUTOIMMUNE DISORDERS | RAJADHYAKSHA V J (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-0782454-A1 | USE OF MURAMYL PEPTIDE COMPOUNDS | PEPTECH (UK) (GB) | 1997-07-09 | — | — | EP | disclosed |
| EP-0768888-A1 | USE OF MURAMYL PEPTIDE COMPOUNDS | PEPTECH (UK) LIMITED (GB) | 1997-04-23 | — | — | EP | disclosed |
| EP-0722332-A1 | COMPOUNDS FOR MEDICINAL USE | PEPTECH (UK) LIMITED (GB) | 1996-07-24 | — | — | EP | disclosed |
| WO-1996009063-A1 | USE OF MURAMYL PEPTIDE COMPOUNDS | PEPTECH(UK) LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| WO-1996001645-A1 | USE OF MURAMYL PEPTIDE COMPOUNDS | PEPTECH(UK) LIMITED (GB) | 1996-01-25 | — | — | WO | disclosed |
| WO-1995010293-A1 | COMPOUNDS FOR MEDICINAL USE | PEPTECH (UK) LIMITED (GB) | 1995-04-20 | — | — | WO | disclosed |
| WO-1993010148-A1 | MURAMYL COMPOUNDS FOR TREATMENT OF SEPTIC SHOCK | PEPTECH (UK) LIMITED (GB) | 1993-05-27 | — | — | WO | disclosed |